Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
Main Authors: | Palma, David A, Haasbeek, Cornelis J A, Rodrigues, George B, Dahele, Max, Lock, Michael, Yaremko, Brian, Olson, Robert, Liu, Mitchell, Panarotto, Jason, Griffioen, GwendolynHMJ, Gaede, Stewart, Slotman, Ben, Senan, Suresh |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433376/ |
Similar Items
-
The Role of Stereotactic Ablative Radiotherapy for Early-Stage and Oligometastatic Non-small Cell Lung Cancer: Evidence for Changing Paradigms
by: Dahele, Max, et al.
Published: (2011) -
Technical know‐how in stereotactic ablative radiotherapy (SABR)
by: Lo, Simon S., et al.
Published: (2016) -
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
by: Comito, Tiziana, et al.
Published: (2014) -
Stereotactic Ablative Radiotherapy for Oligometastatic Disease in Liver
by: Kim, Myungsoo, et al.
Published: (2014) -
Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
by: Goldsmith, Christy, et al.
Published: (2012)